Jun. 22 at 6:00 PM
$MCRB Money is flooding back into clinical stage biotech in what's looking to also be a huge M&A year.
$20B on APGE NUVL just this month. MCRB is NOT going to be acquired - BPs have much bigger fish to fry - but it speaks to the urgency for novel therapies as the patent wall looms.
This also means institutions are more willing to pay up to get in early. Just look at Kanvas Biosciences, microbiome-onc company that raised a
$48M series A with a tenth of the platform, IP, manufacturing know-how etc that Seres has.
Their series A is worth almost as much as Seres' entire market cap.
All it takes is ONE institution or BP to show public confidence in Seres for this to fly.
